<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00706381</url>
  </required_header>
  <id_info>
    <org_study_id>080165</org_study_id>
    <secondary_id>08-DK-0165</secondary_id>
    <nct_id>NCT00706381</nct_id>
  </id_info>
  <brief_title>Thyroid Hormones Homeostasis and Energy Metabolism Changes During Stimulation of Endogenously Secreted Bile Acids (BAs)</brief_title>
  <official_title>Thyroid Hormones Homeostasis and Energy Metabolism Changes During Stimulation of Endogenously Secreted Bile Acids (BAs)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <brief_summary>
    <textblock>
      Postprandial thermogenesis, or thermic effect of food are terms that describe the increase in
      utilization of energy by the human body following a meal. The mechanisms involved in this
      process are believed to differ according to the type of food consumed, whether fat, protein
      or carbohydrate.

      The bile acids (BAs), unique substances secreted by the gall bladder into the gut after a
      meal, play an important role in the absorption of fat and the management of cholesterol
      stores in the body. Recent studies suggest that BAs may also serve as regulators of energy
      expenditure (consumption) in the cells of our body by increasing the production of T3, an
      active form of thyroid hormone. T3 in turn is believed to increase the efficiency with which
      our bodies burn calories thereby generating heat. Although this process has been shown to be
      effective in rodents who demonstrated weight loss after treatment, the role of BAs in humans
      is poorly understood. Thus we do not know whether endogenous (produced by the body) or
      exogenous (taken as medication) BAs play a significant role in the maintenance of body
      weight. We hypothesize that, similarly to rodents, humans will respond to BAs by increasing
      energy expenditure via the production of the active form of thyroid hormone.

      This randomized, cross-over study will look at changes in thyroid hormones and energy
      consumption in response to stimuli of endogenous BA secretion including dietary content, and
      to the intake of pharmacological doses of bile acids.

      Following a two-day period of equilibration diet, 30 healthy volunteers will be randomly
      assigned to receive either a high-fat or high-carbohydrate isocaloric meal followed by a
      6-hour metabolic chamber stay; the next day they will be crossed-over to the alternate
      intervention. During the following three days, the study subjects will again be randomized to
      receive either an intravenous injection of sincalide (the C-terminal octapeptide fragment of
      cholecystokinin) 0.04 mcg/kg or placebo and P.O. placebo, or I.V. placebo and 15 mg/kg of BA
      (ursodiol) with similar metabolic chamber stays and cross-over design.

      The following parameters will be recorded and compared to placebo:

      Energy expenditure

      Substrate utilization

      Spontaneous movements

      Skin and core temperature

      Serial changes in circulating thyroid hormones

      Serial changes in bile acid serum concentrations

      The data gathered from this study will provide greater insight into the physiological and
      molecular mechanism(s) regulating the relation between endogenous bile acid secretion and
      energy metabolism in response to meals, as well as the role of BAs per se on energy
      metabolism.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Postprandial thermogenesis, or thermic effect of food are terms that describe the increase in
      utilization of energy by the human body following a meal. The mechanisms involved in this
      process are believed to differ according to the type of food consumed, whether fat, protein
      or carbohydrate.

      The bile acids (BAs), unique substances secreted by the gall bladder into the gut after a
      meal, play an important role in the absorption of fat and the management of cholesterol
      stores in the body. Recent studies suggest that BAs may also serve as regulators of energy
      expenditure (consumption) in the cells of our body by increasing the production of T3, an
      active form of thyroid hormone. T3 in turn is believed to increase the efficiency with which
      our bodies burn calories thereby generating heat. Although this process has been shown to be
      effective in rodents who demonstrated weight loss after treatment, the role of BAs in humans
      is poorly understood. Thus we do not know whether endogenous (produced by the body) or
      exogenous (taken as medication) BAs play a significant role in the maintenance of body
      weight. We hypothesize that, similarly to rodents, humans will respond to BAs by increasing
      energy expenditure via the production of the active form of thyroid hormone.

      This randomized, cross-over study will look at changes in thyroid hormones and energy
      consumption in response to stimuli of endogenous BA secretion including dietary content, and
      to the intake of pharmacological doses of bile acids.

      Following a two-day period of equilibration diet, 30 healthy volunteers will be randomly
      assigned to receive either a high-fat or high-carbohydrate isocaloric meal followed by a
      6-hour metabolic chamber stay; the next day they will be crossed-over to the alternate
      intervention. During the following three days, the study subjects will again be randomized to
      receive either an intravenous injection of sincalide (the C-terminal octapeptide fragment of
      cholecystokinin) 0.04 mcg/kg or placebo and P.O. placebo, or I.V. placebo and 15 mg/kg of BA
      (ursodiol) with similar metabolic chamber stays and cross-over design.

      The following parameters will be recorded and compared to placebo:

      Energy expenditure

      Substrate utilization

      Spontaneous movements

      Skin and core temperature

      Serial changes in circulating thyroid hormones

      Serial changes in bile acid serum concentrations

      The data gathered from this study will provide greater insight into the physiological and
      molecular mechanism(s) regulating the relation between endogenous bile acid secretion and
      energy metabolism in response to meals, as well as the role of BAs per se on energy
      metabolism.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 23, 2008</start_date>
  <completion_date type="Actual">August 21, 2012</completion_date>
  <primary_completion_date type="Actual">August 21, 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Characterize the role of BAs</measure>
    <time_frame>07-01-2015</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Characterize the metabolic and hormonal</measure>
    <time_frame>07-01-2015</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Role of genetic variants of the type-2 d</measure>
    <time_frame>07-01-2015</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analyze the changes in glucose metabolis</measure>
    <time_frame>07-01-2015</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">39</enrollment>
  <condition>Healthy Volunteers</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sincalide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ursodiol Acid</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>High Fat/Low Fat Diet</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:

        Age greater than or equal to18 years, male or female

        Written informed consent

        EXCLUSION CRITERIA:

        Hypo- or hyperthyroidism (history or serum TSH greater than 5.0 or less than 0.4 miU/L)

        Blood pressure greater than 140/90 mmHg (26) or receiving antihypertensive therapy

        History of cardiovascular disease

        BMI less than or equal to 20 or greater than or equal to 27 Kg/m(2)

        Diabetes mellitus (fasting serum glucose greater than or equal to 126 mg/dL)

        Hyperlipidemia (serum total cholesterol greater than or equal to 240 mg/dL, triglycerides
        greater than or equal to 220 mg/dL, and/or use of antilipemic therapy)

        Liver disease or ALT serum concentrations greater than 1.5 times the upper laboratory
        reference limit

        Hyperbilirubinemia (serum total bilirubin greater than 1.5 mg/dL)

        Renal insufficiency or estimated creatinine clearance less than or equal to 50 mL/min (MDRD
        equation)

        Anemia (Hemoglobin concentration less than or equal to 11.1 g/dL females, and 12.7 g/dL
        males)

        History of cholecystectomy or cholelithiasis (by ultrasound at screening).

        History of malabsorption, or food allergies/intolerances that would preclude participant
        from consuming foods required for study

        Claustrophobia

        History of illicit drug or alcohol abuse within the last 5 years; current use of illicit
        drugs (by history) or alcohol (CAGE greater than 3)

        Psychiatric conditions or behavior that would be incompatible with safe and successful
        participation in this study

        Current use of medications/dietary supplements/alternative therapies known to alter thyroid
        function, energy expenditure or bile acid secretion

        History of weight loss or weight gain of greater than 3 percent body weight over the past 2
        months (self-reported)

        Pregnancy/breastfeeding/hormonal contraceptive use and childbirth within the last 6 months

        Perimenopausal (as self-described within two years from onset of amenorrhea or current
        complaints of hot flashes)

        Current smoker
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kong Y Chen, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://clinicalstudies.info.nih.gov/cgi/detail.cgi?B_2008-DK-0165.html</url>
    <description>NIH Clinical Center Detailed Web Page</description>
  </link>
  <reference>
    <citation>Hill JO. Understanding and addressing the epidemic of obesity: an energy balance perspective. Endocr Rev. 2006 Dec;27(7):750-61. Epub 2006 Nov 22. Review.</citation>
    <PMID>17122359</PMID>
  </reference>
  <reference>
    <citation>Rosen ED, Spiegelman BM. Adipocytes as regulators of energy balance and glucose homeostasis. Nature. 2006 Dec 14;444(7121):847-53. Review.</citation>
    <PMID>17167472</PMID>
  </reference>
  <reference>
    <citation>Blaak EE, Hul G, Verdich C, Stich V, Martinez JA, Petersen M, Feskens EF, Patel K, Oppert JM, Barbe P, Toubro S, Polak J, Anderson I, Astrup A, Macdonald I, Langin D, SÃ¸rensen T, Saris WH; NUGENOB Consortium. Impaired fat-induced thermogenesis in obese subjects: the NUGENOB study. Obesity (Silver Spring). 2007 Mar;15(3):653-63.</citation>
    <PMID>17372316</PMID>
  </reference>
  <verification_date>August 4, 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 26, 2008</study_first_submitted>
  <study_first_submitted_qc>June 26, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2008</study_first_posted>
  <last_update_submitted>October 18, 2017</last_update_submitted>
  <last_update_submitted_qc>October 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Deiodinase</keyword>
  <keyword>Bile Acids</keyword>
  <keyword>Cholecystokinin</keyword>
  <keyword>Thyroid Hormones</keyword>
  <keyword>Energy Expenditure</keyword>
  <keyword>Health Volunteer</keyword>
  <keyword>HV</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Bile Acids and Salts</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

